T. Rowe Price Associates’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

T. Rowe Price Associates’s Portfolio CADX Stock Details CADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-5,975,818	Closed	-$54.1M	–	2547
2013 Q4	$54.1M	Sell	5,975,818 -1,239,000	-17%	-$8.95M	0.01%	811
2013 Q3	$45.5M	Sell	7,214,818 -170,323	-2%	-$1.08M	0.01%	847
2013 Q2	$50.4M	Buy	+7,385,141	New	+$51.4M	0.01%	781

Other funds holding CADX

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

T. Rowe Price Associates's CADX Position: Q1 2014 in Review

T. Rowe Price Associates sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 5,975,818 shares — an estimated $54.1M sold.

T. Rowe Price Associates first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $54.1M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

T. Rowe Price Associates reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
T. Rowe Price Associates sold 5,975,818 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $54.1M.
T. Rowe Price Associates first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
T. Rowe Price Associates's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $54.1M in Q4 2013.
3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on T. Rowe Price Associates's 13F filing for Q1 2014, filed 15 May 2014.